Group 1 - The core index of the China Securities Index for Food and Major Consumer Goods Retail has shown a recent upward trend, with a 4.43% increase over the past month, a 0.49% increase over the past three months, and a year-to-date decline of 3.88% [1] - The index is composed of listed companies in the food and drug retail sector, reflecting the overall performance of these companies, with a base date of December 31, 2004, set at 1000.0 points [1] - The top ten weighted companies in the index include Yonghui Supermarket (6.49%), Digital China (6.34%), Shanghai Pharmaceuticals (4.65%), Yifeng Pharmacy (4.23%), and others [1] Group 2 - The market share of the index's holdings is divided between the Shanghai Stock Exchange (53.16%) and the Shenzhen Stock Exchange (46.84%) [1] - In terms of industry composition, the index shows that pharmaceutical commerce accounts for 44.64%, supermarkets and convenience stores for 20.60%, specialty retail for 20.32%, and department stores for 14.44% [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 文/新浪财经上海站 陈秀颖 2025年上半年，中国创新药行业在政策红利与国际化突破的双重助力下迎来高光时刻，Wind数据显 示，A股创新药板块80家企业中，16家已发布中报预告。头部企业凭借技术壁垒与商业化能力实现爆发 式增长。 | 证券简称 | 预告净利润同比增长 | | 预告净利润同比增 董事长 | 总经理 | | --- | --- | --- | --- | --- | | | 上限 | 长下限 | | [交易日期] 最新 [交易日期] 最新 | | | [报告期] 今年中报 | [报告期] 今年中报 | | | | | [单位] %↓ | [单位] % | | | | 双鹭药业 | 356.24 | | 237.95 徐明波 | 徐明波 | | 全诺生物 | 332.10 | | 253.54 文永均 | 文永均 | | 步长制药 | 205.94 | | 110.88 赵涛 | #x15 | | 通化东宝 | 194.30 | | 194.30 李佳鸿 | 冷春生 | | 微芯生物 | 173.00 | | 173.00 X ...

Policy Developments - The National Healthcare Security Administration (NHSA) held the first session of a series of discussions on supporting innovative drugs and medical devices, with over 20 representatives from pharmaceutical companies, research institutions, and medical organizations participating. The meeting emphasized the NHSA's commitment to supporting true innovation and the importance of a comprehensive value assessment for innovative products to enhance healthcare resource utilization and better serve public health [2]. Drug and Device Approvals - Shanghai Pharmaceuticals announced that its subsidiary's tranexamic acid injection has received approval from the National Medical Products Administration (NMPA) after passing the consistency evaluation for generic drugs. This drug is primarily used for various bleeding conditions caused by primary fibrinolysis [4]. - Huason Pharmaceutical received re-registration approval for three drugs from the Chongqing Drug Administration, including Ganqi Bingmei Tablets, Liuwei Anshen Capsules, and Silotazol Tablets [5]. - Huiren Pharmaceutical's subsidiary received approval for the listing of methochlorpromazine hydrochloride raw materials, which are used for preventing postoperative nausea and vomiting, as well as treating nausea related to migraines and radiation therapy. Additionally, the subsidiary received a medical device registration certificate for a sterile, single-use syringe [6]. Capital Market Activities - ST Jingfeng announced the sale of a 51% stake in its subsidiary Jiangxi Yanhua Pharmaceutical to Jiangxi Shaoyang Pharmaceutical for a price of 142,500 yuan. Following this transaction, Jiangxi Yanhua will no longer be included in the company's consolidated financial statements [8]. Industry Events - Sichuan University West China Hospital successfully completed the first implanted brain-machine interface surgery in Western China for a patient with spinal cord injury, allowing the patient to control a mechanical hand using brain signals [10][11]. - Samsung Medical's subsidiary signed a procurement framework contract in Brazil worth approximately 341 million yuan, which represents 2.33% of the company's audited revenue for 2024 [12].

Group 1 - Haitong Development reported a net profit of 86.87 million yuan for the first half of 2025, a year-on-year decrease of 64.14% [1] - Haitong Development achieved an operating income of 1.8 billion yuan, a year-on-year increase of 6.74% [1] - Crystal Integrated expects a net profit increase of 39.04% to 108.55% for the first half of 2025, with projected revenue between 5.07 billion yuan and 5.32 billion yuan [1] Group 2 - Aerospace Universe anticipates a net profit increase of 50.59% for the first half of 2025, with a projected net profit of 34.38 million yuan [2] - Aerospace Universe's net profit excluding non-recurring gains is expected to grow by 94.90% [2] Group 3 - Guodian Power reported a total power generation of 206.03 billion kWh for the first half of 2025, a year-on-year decrease of 3.61% [3] - The company's market-based transaction electricity accounted for 91.84% of the total electricity sold [3] Group 4 - Shanghai Pharmaceuticals announced that its tranexamic acid injection has passed the consistency evaluation for generic drugs [5] - The drug is primarily used for treating various bleeding disorders [5] Group 5 - Sanyou Chemical received approval to issue up to 900 million yuan in technology innovation corporate bonds [7] - The bond issuance is valid for 24 months from the date of approval [7] Group 6 - Baiyuntian's BAT4406F injection drug has received approval for clinical trials for additional indications [9] - The drug is a next-generation fully human anti-CD20 antibody [9] Group 7 - Huason Pharmaceutical received three drug re-registration approval notices [10] - The approved drugs include Ganji Bingmei tablets and other formulations [10] Group 8 - Shanying International plans to establish the Zhiyuan Fund with a total scale of 100 million yuan [13] - The fund will primarily invest in product companies related to industrial scenarios [13] Group 9 - Yiqiu Resources announced the sale of two properties in Malaysia for a total of approximately 3.67 million yuan [15] - The sale is part of the company's asset management strategy [15] Group 10 - Guizhou Bailing plans to apply for loans totaling no more than 920 million yuan from multiple banks [16] - The loans will be used to replace maturing loans and supplement working capital [16] Group 11 - Samsung Medical's subsidiary won a transformer procurement contract in Brazil worth approximately 341 million yuan [16] - The contract is part of the company's expansion into international markets [16] Group 12 - Changying Tong expects a net profit increase of 72.12% to 110.33% for the first half of 2025 [17] - The projected revenue is between 173 million yuan and 211 million yuan [17] Group 13 - Canqin Technology anticipates a net profit increase of 50.14% to 61.85% for the first half of 2025 [17] - The expected revenue is between 286 million yuan and 290 million yuan [17] Group 14 - Daya Shengxiang signed a lease agreement with an annual rent of 17 million yuan for a production facility [18] - The lease term is for 3 years and 4 months, including a 4-month rent-free period [18] Group 15 - Zhongzai Zihuan announced the resignation of its general manager due to work adjustments [20] - The company will appoint an interim general manager while searching for a permanent replacement [20] Group 16 - Fuwei Co. received a project notification from a well-known luxury brand for seat development [22] - The total sales amount for the project is expected to reach 4.9 billion yuan [22] Group 17 - Meili Technology's application for convertible bonds has been accepted by the Shenzhen Stock Exchange [26] - The issuance is subject to further approval from regulatory authorities [26] Group 18 - Jinzhik Technology announced a stock suspension due to potential control changes [27] - The suspension is expected to last no more than two trading days [27] Group 19 - Zhongtian Technology plans to distribute a cash dividend of 3 yuan per 10 shares [28] - The dividend distribution date is set for July 25, 2025 [28] Group 20 - Huahai Chengke plans to distribute a cash dividend of 0.2002 yuan per share [30] - The dividend distribution date is set for July 29, 2025 [30] Group 21 - Dasheng Intelligent won a smart transportation project contract worth 122 million yuan [31] - The project involves comprehensive monitoring systems for urban rail transit [31] Group 22 - Dongyue Silicon reported a fire incident affecting production operations [32] - The fire has been controlled, but the extent of damage is still being assessed [32] Group 23 - Shaanxi Guotou A reported a net profit of 726 million yuan for the first half of 2025, a year-on-year increase of 5.74% [35] - The company's operating income decreased by 2.95% [35] Group 24 - Yibo Technology announced a plan to reduce shareholding by up to 3% [37] - The reduction is due to the shareholder's funding needs [37] Group 25 - Xiling Information announced a stock suspension due to potential control changes [39] - The suspension is expected to last no more than two trading days [39] Group 26 - Tianli Lithium Energy plans to reduce shareholding by 4.55% through block trading [40] - The reduction is due to the fund's operational timeline nearing its end [40] Group 27 - Sihui Fushi announced plans for a combined shareholding reduction of up to 3% [42] - The reduction is due to the shareholders' personal funding needs [42] Group 28 - Jinma Leisure announced a plan for a combined shareholding reduction of up to 4.83% [44] - The reduction is due to personal funding needs of the controlling shareholder and executives [44] Group 29 - *ST Zitian's stock may be terminated due to financial reporting issues [46] - The company is under regulatory scrutiny for failing to rectify its financial statements [46]

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 * 僅供識別 （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於氨甲環酸注射液通過仿製藥一致性評價的公告》僅 供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 7 月 22 日 证券代码：601607 证券简称 ...

上海医药集团股份有限公司 证券代码：601607 证券简称：上海医药 编号：临 2025-071 关于氨甲环酸注射液通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 氨甲环酸注射液主要用于急性或慢性、局限性或全身性原发性纤维蛋白溶解 亢进所致的各种出血。弥散性血管内凝血所致的继发性高纤溶状态，在未肝素化 前，一般不用本品。 近日，上海医药集团股份有限公司（以下简称"公司"）下属上海信谊金朱 药业有限公司（以下简称"信谊金朱"）的氨甲环酸注射液（以下简称"该药品"） 收到国家药品监督管理局（以下简称"国家药监局"）颁发的《药品补充申请批 准通知书》（通知书编号：2025B03210），该药品通过仿制药质量和疗效一致 性评价。 一、该药品基本情况 药品名称：氨甲环酸注射液 剂型：注射剂 规格：5ml：0.25g 注册分类：化学药品 申请人：上海信谊金朱药业有限公司 原批准文号：国药准字 H31021856 审批结论：本品通过仿制药质量和疗效一致性评价。 二、该药品相关的信息 氨甲环酸注射液由日本第一 ...

Core Viewpoint - The special verification opinion issued by Beijing Hankun Law Firm confirms that Shanghai Wankexin Biotechnology Partnership (Limited Partnership) does not have an actual controller, which is significant for its equity changes [2][9]. Group 1: Company Overview - Shanghai Wankexin Biotechnology Partnership (Limited Partnership) is registered in the China (Shanghai) Free Trade Zone with a total capital contribution of 763.01 million RMB [3][5]. - The executing partner of Wankexin is Shanghai Shanshi Biomedical Management Consulting Co., Ltd., which holds a 0.001% partnership share [4][6]. Group 2: Equity Structure - The partnership structure includes Shanghai Shanshi Biomedical Management Consulting Co., Ltd. (0.001%), Shanghai Biomedical M&A Private Fund Partnership (Limited Partnership) (80.209%), and Shanghai Pharmaceutical (Group) Co., Ltd. (19.790%) [5][6]. - The total capital contribution of the partnership is set to change to 763.01 million RMB following the entry of a new partner, Shanghai Pharmaceutical (Group) Co., Ltd., which will contribute 151 million RMB [5][6]. Group 3: Control Structure - The executing partner, Shanghai Shanshi Biomedical, has the authority to represent the partnership and make decisions regarding partnership affairs, indicating that it acts as the controlling entity [6][9]. - Shanghai Shanshi Biomedical is jointly owned by Shanghai Shanshi Capital Management Co., Ltd. and Lubuqa Enterprise Management Consulting Partnership (Limited Partnership), each holding 50% of the shares [7][9]. Group 4: Conclusion - The verification opinion concludes that there is no single shareholder capable of controlling the shareholder meeting or board of directors of Shanghai Shanshi Biomedical, thus confirming that both Shanghai Wankexin and Shanghai Shanshi Biomedical do not have an actual controller [9][10].

Group 1 - The Shanghai Reform and Development Theme Index closed at 2523.18 points, with a trading volume of 29.016 billion yuan, reflecting a 0.51% increase [1] - Over the past month, the index has risen by 3.32%, and by 8.67% over the last three months, while it has decreased by 0.07% year-to-date [1] - The index primarily selects stocks from companies listed on the Shanghai Stock Exchange, focusing on themes such as the "Belt and Road" initiative, "Four Centers," and Free Trade Zone development [1] Group 2 - The top ten weighted stocks in the index include SAIC Motor (8.68%), Shanghai Port Group (7.73%), and Pudong Development Bank (7.62%) [1] - The index's holdings are entirely composed of stocks from the Shanghai Stock Exchange, with the industrial sector representing 29.98%, financial sector 22.30%, and consumer discretionary 18.22% [2] - The index samples are adjusted quarterly, with changes implemented on the next trading day following the second Friday of March, June, September, and December [2]

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司 2024 年年度權益分派實施公告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 7 月 12 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 * 僅供識別 证券代码：601607 证券简称：上海医药 ...

证券代码：601607 证券简称：上海医药 公告编号：临2025-070 上海医药集团股份有限公司 每股分配比例 A 股每股现金红利0.29元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/7/17 | － | 2025/7/18 | 2025/7/18 | 差异化分红送转： 否 一、通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 6 月 26 日的2024年年度股东大会审议通过。 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 二、分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体 A 股股东。 H 股 股 东 的 现 金 分 红 有 关 情 况 详 见 本 公 司 在 香 港 联 合 交 易 所 有 限 公 司 网 ...